What Is Commercial Due Diligence?
Commercial due diligence answers the question financial due diligence cannot: is this revenue defensible, and will it grow at the pace your entry multiple assumes? Most processes answer a different question. They describe the company: market size, competitive position, satisfaction scores, price against a benchmark. Description confirms what you already believed. Diligence should test the thesis, not describe the company, and the difference surfaces in year two of the hold, when you have the least runway left to fix it.
What Commercial Due Diligence Evaluates
Commercial due diligence (CDD) is the evaluation of a target company's commercial viability, revenue quality, market position, and growth potential before an acquisition closes. Financial due diligence asks whether the revenue is real. Commercial due diligence asks whether it is defensible, repeatable, and able to grow at the rate the investment thesis requires. Both are required. The pricing dimension sits almost entirely in CDD.
A complete CDD covers the market, the customer base, the commercial infrastructure of pricing, sales, and go-to-market, the management team's commercial capability, and the value creation available post-close. Each area produces a risk assessment, which the investment committee prices, and an opportunity estimate, which the operating team inherits. This page is written for private equity and growth equity buyers of B2B software, where pricing, packaging, and retention carry most of the thesis. Once you are past close, the PE pricing diligence and value creation guide picks up where this page ends.
The scope of a complete CDD
The Cost Shows Up in Year Two
You paid a multiple for a set of beliefs. If you paid 9x ARR for a vertical SaaS company, you believed net revenue retention would expand from 104 to 112 percent over the hold, that pricing power would carry 15 percent annual ACV growth without meaningful churn, and that the ideal customer profile was defensible enough not to commoditize before exit. Those beliefs are hypotheses. The job of commercial due diligence is to test them before you write the check.
The cost of CDD that describes instead of tests stays invisible for 18 to 24 months, then surfaces as symptoms that look operational: longer sales cycles, churn above model in one tier, a pricing initiative stalled because sales is resisting it. Do the math on your own deal. A target entering at $50M ARR with a 100 percent NRR assumption that actually runs at 92 percent loses $4M of ARR a year that was supposed to compound. Over a 36-month hold, $12M of ARR is missing from the exit base. At a 6x exit multiple, that is $72M of enterprise value, and every dollar of it was visible in the cohort table, the exception log, and the switching-cost interviews nobody ran.
Three Hypotheses to Write Before the Data Room Opens
Your entry multiple is an expression of beliefs about future commercial performance. Before you request access, write down the three commercial beliefs that justify the top 20 percent of your entry price. Not “we think there is pricing upside.” Something you can be wrong about: “We believe NRR is structurally above 105 percent because the product is embedded in a workflow that is expensive to replace, and that this retention profile will hold through a 15 percent price increase at renewal in year two.” That sentence names a mechanism, predicts a number, and states the condition under which it fails.
If you cannot write that sentence, you do not have a commercial thesis. You have a market narrative, which is different. A narrative can be confirmed by any data room. A hypothesis can be rejected by the right one, and rejection is what you are looking for.
The retention hypothesis
“NRR holds above X percent because [the mechanism that makes the product expensive to leave].” The test is cohort behavior, not the blended number.
The price hypothesis
“The base absorbs a Y percent increase at renewal because switching cost exceeds the increase.” The test is what customers say the increase would trigger, and what repriced cohorts actually did; willingness to pay by segment is the evidence to ask for.
The contract value hypothesis
“ACV moves from $42,000 to $55,000 as we move upmarket because [a segment already pays it].” The test is the last three renewals in that band and what set the final price.
Data Requests That Test, Not Describe
For the retention hypothesis above, the data request is not “provide NRR for the last four quarters.” It is: “provide cohort retention by acquisition year and plan tier for the last 36 months, with expansion and contraction broken out by tenure band, and the retention data for any cohort that has experienced a price change.” The specificity of the request tells management what you are testing. Good teams welcome it. Teams that resist a specific request are telling you something you needed to know.
The contract extract for the waterfall
Every contract from the last 24 months with list price, negotiated price, post-signature credits and concessions, and the account's tenure at signing. Aggregate ARR cannot show discount norms. This can. Ask for the raw CRM export, not the curated version.
The cohort retention table
NRR by acquisition year, plan tier, and segment for 36 months, with any repriced cohort flagged. Any SaaS company with working billing infrastructure can produce this in 48 hours. If it cannot, or will not, that is a finding.
The discount exception log
Every deal in the last 24 months above the stated policy ceiling: who approved it, the stated reason, and how the account has performed since. This separates a structural problem from a cultural one, and each needs a different post-close intervention.
The pricing change history
Every list or tier change in 36 months: what changed, when, for which segment, and what retention did in the affected cohort afterward. It is the record of pricing experiments the company has already run, most of them by accident. It takes management 30 minutes to pull, and it is the document most often never requested.
Add one line to your standard data room template today: retention for every cohort that experienced a price change in the last 36 months. It will not slow a deal down. The commercial diligence checklist for PE-backed SaaS has the full request list by workstream, with the seven findings that took $27M off one ask.
The One Customer Interview Question
Most CDD interviews ask customers to rate satisfaction, describe use cases, and comment on alternatives. Useful context. None of it tests a pricing hypothesis. Ask this instead: “If the price of this product increased 20 percent at your next renewal, what would happen inside your organization?” The answer in your first five interviews tells you more about pricing power than any benchmark comparison. It also tells you whether pricing power is a product property or a budget property. Products with real switching cost survive a 20 percent increase because the switching cost is larger than the increase. Products without it do not, whatever the satisfaction score says.
Two follow-ups sharpen it. “What would it cost your organization to replace this product, in migration time, retraining, and risk?” That is the switching cost in the customer's own units. “Under what circumstances would you stop using this or significantly cut your spend?” That is the falsification question. It is harder to answer than a rating, which is exactly why it is worth asking.
Run at least twelve interviews and choose the sample deliberately: three churned customers, three from the highest ACV tier, three from the fastest-growing segment. Reference calls with the seller's happiest accounts are selection-biased toward the accounts that will never test your thesis. Two hours with churned customers surfaces risks that twenty hours of document review will not.
Pricing Prerequisites Before IC
A deal thesis is a set of commercial assumptions. Before the investment committee meets, write down the three pricing assumptions your entry multiple depends on: “NRR expands from 103 to 110 percent as we raise prices at renewal,” “ACV rises from $42,000 to $55,000 as we move upmarket,” “gross retention holds above 88 percent through a price restructure in year two.” Each is a prerequisite. CDD's job is to confirm or refute each one before you close.
Then hold a rule that feels uncomfortable: treat ambiguous findings as rejections, not maybes. The most dangerous line in a CDD report is “data is insufficient to assess pricing upside with confidence.” It gets filed as a yellow flag. It should be read as a rejection of the assumption until positive evidence exists. If you cannot confirm pricing power before close, you are assuming it, and Simon-Kucher's State of Pricing 2025 found that only 65 percent of companies truly possess pricing power. Roughly one in three does not. Your thesis assumes yours does.
Close the loop with a stress test. Take the pricing ceiling and switching cost from the interviews and run the model's NRR and ACV assumptions through three scenarios: best case, base case, and a case where the first price increase at renewal triggers 10 percent more churn than base. If the deal still works in the downside, the commercial thesis is robust. If it does not, adjust the entry valuation or make a pre-close pricing governance audit a condition of signing.
Build the Waterfall From Contracts, Not the CIM
The CIM reports an average discount. The CRM discount field reports what reps typed in. Neither is the pocket price. When you build the price waterfall from executed contracts, amendments, and invoices, you find what appears in neither: off-invoice concessions, free implementation periods, extended payment terms, bundled services hours. A company reporting $50,000 ACV with 35 percent average discounts and zero renewal uplift does not have a $50,000 ACV business. It has a $32,000 ACV business with aspirational branding, and a repricing thesis built on the $50,000 starts from a baseline that is 36 percent too high.
Marn and Rosiello introduced the pocket price waterfall in the Harvard Business Review in 1992, and it is still the cleanest instrument for this. Pull the deal-level extract for the previous 24 months and calculate the average discount by deal size, by rep, by segment, and by quarter. You are looking for three patterns: a discount rate trending up over six or more quarters, which is market or competitive pressure; a small number of reps driving most of the discounting, which is a governance problem; and a gap that widens with deal size, which means the enterprise pricing model is broken. A waterfall gap above 20 percent in a business more than three years old is an architecture finding, not a sales execution finding. Treat that as a planning rule, not a statistic.
The pocket price is the only price that matters. Everything above it is a story the seller is telling you. McKinsey's The Power of Pricing puts the operating profit lift from a 1 percent improvement in realized price at roughly 11 percent for the average company, which is why the list-to-pocket gap belongs in the enterprise value calculation and not in an appendix. The price waterfall concept page has the mechanics. The pocket price waterfall paper shows a 36 percent leak in one channel that the blended figure hid.
Cohort NRR: The 109% That Was 91%
Aggregate NRR of 109 percent can sit on top of a base that is quietly shrinking. Marlow Payroll, an illustrative payroll platform at $58M ARR, went to a growth equity buyer with 109 percent headline NRR and strong top-line momentum. The CDD report noted the NRR as a positive signal. No decomposition was performed. Six months post-close the number began to slide. The 109 percent had been built on one large expansion from a single enterprise account that had since plateaued. Underlying NRR without that account was 97 percent. Customers acquired in the two most recent cohort years were running at 91 percent.
None of that was hidden. It was in the billing data the whole time. Read the cohort table as a record of experiments, not a performance summary. When a cohort's NRR shifted after a price change, that was a pricing experiment. When one segment's retention diverged from the book, that was a segmentation experiment. When expansion dried up in a specific tenure band, that was a packaging experiment. Actual behavior beats stated intent in every interview you will run.
Three cuts to insist on. NRR by acquisition year, to see whether the business is getting better or worse at keeping and growing customers over time. NRR by acquisition channel, because inbound and outbound cohorts often retain differently, and that decides post-close go-to-market allocation. NRR by tenure band, because the third-year renewal is where a product that solved an acute problem stops earning its price. Then separate gross retention, expansion, and contraction, and check how the number was calculated. A figure that excludes implementation fees and counts one-time services as expansion describes a different business than the one in the deck. The operator's guide to net revenue retention covers the compounding math once you own the asset.
What Buyers Test in the Management Interview
The management interview is where commercial discipline separates from commercial narrative. Four questions do most of the work.
Q: Can the CEO explain the pricing rationale without referencing competitors?
A CEO who says the company is priced in line with the market, or below a named competitor, has no pricing strategy. A CEO who explains the value metric, why it was chosen, and what the willingness-to-pay research showed has commercial depth.
Q: Does the VP of Sales know the discount rate by segment and by rep?
If the answer is not within two or three points from memory, the company does not have pricing governance. The data exists in the CRM. Nobody is accountable for it, and that takes six to nine months to fix post-close.
Q: What is cohort NRR by year of acquisition?
A team that answers with the blended number has not looked. A team that answers by vintage, and can say which cohorts are weakest and why, has been managing revenue quality rather than reporting it.
Q: Why do customers churn, and at what price?
Churn from product gaps needs product investment. Churn from price needs pricing or packaging work. Churn from poor fit needs ICP refinement. One blended churn rate hides which intervention the plan has to fund.
The Four CDD Workstreams
A complete commercial due diligence is organized into four workstreams. Each produces a risk assessment and an opportunity estimate that feed the investment thesis and the 100-day plan.
Market assessment
Addressable market and growth rate, competitive structure, buyer purchase criteria, and the target's position against its top three competitors on price, product, and brand. It answers whether the market can support the growth in the thesis, and it is the workstream most processes already do well.
Customer analysis
Concentration (what share of ARR is at risk if the top five accounts leave), cohort NRR by vintage, churn by driver and segment, and expansion quality: product triggers, or a customer success motion that needs constant effort to sustain.
Commercial infrastructure
Pricing architecture and governance, the sales qualification and conversion process, the go-to-market motion, and the commercial data infrastructure. The pricing maturity score, the pocket price gap, the packaging review, and the willingness-to-pay assessment all live here, and each finding carries a specific intervention and a modeled EBITDA impact. The architecture the target should have is laid out in the SaaS pricing strategy guide.
Management quality
The commercial IQ and execution capability of the leadership team, tested with the four questions above. A strong plan in the hands of a weak commercial team is worth less than a moderate plan with a strong one.
From Findings to the 100-Day Plan
CDD output connects to the deal in two places. It validates or challenges the entry multiple, and it specifies the value creation plan. A target with a revenue quality score of 4 out of 5 (stable cohort NRR, low concentration, written governance, organic expansion) deserves a higher multiple than a 2 (declining recent vintages, high concentration, oral governance, expansion that depends on customer success effort). If the model assumed 105 percent NRR and diligence confirmed 91, the supportable price moves. A diligence that does not produce that conversation was expensive whatever the fee.
Then every finding maps to an intervention with an owner, a modeled EBITDA impact, and a date. A 20 percent pocket price gap maps to a governance project. A flat tier mix maps to a packaging relaunch. Declining cohort NRR in recent vintages maps to an expansion motion redesign. The deliverable becomes the commercial section of the 100-day plan, so the operating team enters with a prioritized agenda instead of spending its first 60 days rediscovering what the report already said. The lever ranking behind those modeled impacts is in EBITDA margin improvement for SaaS.
Most reports never get that far. Pemberton Software, illustrative, $38M ARR: diligence flagged 93 percent NRR and a comp plan that paid for volume over quality. The deal closed with no price adjustment and neither finding in the 100-day plan. At month 18, NRR was 89 percent and the comp plan unchanged. Remediation cost $1.4M of customer success investment plus $2.1M of erosion that could not be recovered. The diligence fee was $140K. Acted on at close, it would have returned roughly 22 times its cost. Filed, it returned nothing. Pull your last three CDD reports and count the findings that never became an owner and a date. The five diligence layers paper shows how the layers stack on one deal; the PE pricing diligence guide runs the post-close program.
What a 30-Day CDD Sprint Covers
You have a 100-day window after close to set the commercial agenda before decisions start costing political capital you have not yet built. What you do in the 30 days before close decides whether you enter that window with a roadmap or with questions. Four numbers you must know before you sign: realized price as a percentage of list, NRR by cohort, CAC payback by channel, and the share of revenue in accounts that have never had a price increase. Without all four you do not have commercial due diligence. You have commercial hope.
Week 1: requests out on day one
The contract extract, the cohort table, the exception log, the pricing change history. Schedule the twelve customer interviews now, churned accounts included, because they take longest to arrange.
Weeks 2 to 3: build and interview
Build the waterfall from contracts. Decompose NRR by vintage, channel, and tenure. Run the interviews. Separately, ask three to five reps and three to five deal desk approvers how a non-standard deal gets approved. Inconsistent answers mean the governance is an oral tradition, and oral traditions do not survive the leadership change you may be planning.
Week 4: synthesize and stress-test
Score the five pricing dimensions. Run the model through the three scenarios. Write every finding as an intervention with an owner and a modeled impact, and put the price adjustment conversation on the table before IC, not after.
If you are already post-close and CDD did not answer these questions, run the same sprint now. What you find is your value creation plan.
Confirmed Below Market, Never Tested Pricing Power
I have seen this one more than once. The name is invented. The pattern is not.
The approach. Ridgeline Project Software, acquired at 8x ARR. CDD confirmed the product was priced 18 percent below comparable tools and flagged “pricing upside at renewal.” Management's 100-day plan included a pricing initiative.
Where it broke. Nobody tested whether the product's stickiness would carry the increase. Interviews covered feature comparison, not value attribution. Nobody asked what a 20 percent increase would trigger.
Consequences. Year two, a 22 percent average increase at renewal. Gross retention in the affected cohort fell from 88 to 79 percent. Fourteen customers of three or more years left. Cohort NRR went from 107 to 91. The exit buyer regressed forward NRR at 93 percent and paid 7.2x against an 8x entry. MOIC of 1.8x on a deal underwritten to 3.2x.
The corrected approach. “Below market” is a description. Test whether the base stays at market price before you model the increase, and size the increase by cohort rather than as one number.
Company names and figures in worked examples are illustrative.
Commercial Due Diligence: Common Questions
What is commercial due diligence, and how is it different from financial due diligence?
What should a commercial due diligence checklist for a SaaS target include?
How long does commercial due diligence take?
What is revenue quality due diligence?
How do you test pricing power in commercial due diligence?
Why does headline NRR mislead in commercial due diligence?
How does commercial due diligence feed the 100-day plan?
Test the thesis before the close, not after
FintastIQ runs commercial due diligence that starts from your hypotheses rather than the seller's deck: the waterfall from contracts, cohort NRR by vintage, the interview question that tests pricing power, and a post-close roadmap with a modeled EBITDA impact for each finding. Which of your three hypotheses could the current data room reject?